<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400800</url>
  </required_header>
  <id_info>
    <org_study_id>MDCO-PCS-17-08</org_study_id>
    <nct_id>NCT03400800</nct_id>
  </id_info>
  <brief_title>Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol</brief_title>
  <acronym>ORION-11</acronym>
  <official_title>A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) or ACSVD Risk-Equivalents and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, placebo-controlled, double-blind, randomized study in participants with&#xD;
      ASCVD or ASCVD-Risk equivalents and elevated LDL-C despite maximum tolerated dose of LDL-C&#xD;
      lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC)&#xD;
      inclisiran injection(s). The study will be an international multicenter study (non-United&#xD;
      States).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">August 27, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in LDL-C From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540</measure>
    <time_frame>Baseline, Day 90 to Day 540</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change In LDL-C From Baseline To Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540</measure>
    <time_frame>Baseline, Day 90 to Day 540</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Cholesterol From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Non-HDL-C From Baseline to Day 510</measure>
    <time_frame>Baseline, Day 510</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1617</enrollment>
  <condition>ASCVD</condition>
  <condition>Risk Factor, Cardiovascular</condition>
  <condition>Elevated Cholesterol</condition>
  <arm_group>
    <arm_group_label>Inclisiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inclisiran Sodium</intervention_name>
    <description>Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
    <arm_group_label>Inclisiran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
    <arm_group_label>Saline Solution</arm_group_label>
    <other_name>Saline Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants may be included if they meet all of the following inclusion criteria prior to&#xD;
        randomization:&#xD;
&#xD;
          1. Male or female participants ≥18 years of age.&#xD;
&#xD;
          2. History of ASCVD (coronary heart disease [CHD], cardiovascular disease [CVD], or&#xD;
             peripheral arterial disease [PAD]).&#xD;
&#xD;
          3. Serum LDL-C ≥1.8 millimole (mmol)/liter (L) (≥70 mg/dL).&#xD;
&#xD;
          4. Fasting triglyceride &lt;4.52 mmol/L (&lt;400 mg/dL) at screening.&#xD;
&#xD;
          5. Calculated glomerular filtration rate &gt;30 mL/min by estimated glomerular filtration&#xD;
             rate (eGFR) using standardized clinical methodology&#xD;
&#xD;
          6. Participants on statins should be receiving a maximally tolerated dose.&#xD;
&#xD;
          7. Participants not receiving statins must have documented evidence of intolerance to all&#xD;
             doses of at least 2 different statins.&#xD;
&#xD;
          8. Subjects on lipid-lower therapies (such as a statin and/or ezetimibe) should be on a&#xD;
             stable dose for ≥30 days before screening with no planned medication or dose change&#xD;
             during study participation.&#xD;
&#xD;
          9. Subjects were willing and able to give informed consent before initiation of any&#xD;
             study-related procedures and willing to comply with all required study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants will be excluded from the study if any of the following exclusion criteria&#xD;
        apply prior to randomization:&#xD;
&#xD;
          1. New York Heart Association (NYHA) class IV heart failure.&#xD;
&#xD;
          2. Uncontrolled cardiac arrhythmia.&#xD;
&#xD;
          3. Uncontrolled severe hypertension.&#xD;
&#xD;
          4. Active liver disease.&#xD;
&#xD;
          5. Females who are pregnant or nursing, or who are of childbearing potential and&#xD;
             unwilling to use at least 2 methods of highly effective contraception (failure rate&#xD;
             less than 1% per year) (for example, combined oral contraceptives, barrier methods,&#xD;
             approved contraceptive implant, long-term injectable contraception, or intrauterine&#xD;
             device) for the entire duration of the study. Exemptions from this criterion:&#xD;
&#xD;
               1. Women &gt;2 years postmenopausal (defined as 1 year or longer since last menstrual&#xD;
                  period) and more than 55 years of age.&#xD;
&#xD;
               2. Postmenopausal women (as defined above) and less than 55 years of age with a&#xD;
                  negative pregnancy test within 24 hours of randomization.&#xD;
&#xD;
               3. Women who are surgically sterilized at least 3 months prior to enrollment.&#xD;
&#xD;
          6. Males who are unwilling to use an acceptable method of birth control during the entire&#xD;
             study period (such as condom with spermicide).&#xD;
&#xD;
          7. Treatment with other investigational products or devices within 30 days or 5&#xD;
             half-lives of the screening visit, whichever is longer.&#xD;
&#xD;
          8. Treatment (within 90 days of screening) with monoclonal antibodies directed towards&#xD;
             PCSK9.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a&#xD;
        participant's potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ray Kausik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College of London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site 11420-002</name>
      <address>
        <city>Chomutov</city>
        <zip>43001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11420-003</name>
      <address>
        <city>Uherské Hradiště</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-006</name>
      <address>
        <city>Berlin</city>
        <zip>12567</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-002</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-003</name>
      <address>
        <city>Frankfurt</city>
        <zip>60313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-007</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11049-001</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11036-001</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11036-004</name>
      <address>
        <city>Debrecen</city>
        <zip>4025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11036-002</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11036-003</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-018</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-016</name>
      <address>
        <city>Brzozów</city>
        <state>Podkarpackie</state>
        <zip>36-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-019</name>
      <address>
        <city>Ruda Śląska</city>
        <state>Slaskie</state>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-011</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-004</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-017</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-542</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-005</name>
      <address>
        <city>Gdynia</city>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-007</name>
      <address>
        <city>Katowice</city>
        <zip>04-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-012</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-014</name>
      <address>
        <city>Kraków</city>
        <zip>31-216</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-003</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-008</name>
      <address>
        <city>Lublin</city>
        <zip>20-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-001</name>
      <address>
        <city>Poznań</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-013</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-015</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-009</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-006</name>
      <address>
        <city>Warszawice</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-002</name>
      <address>
        <city>Wrocław</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11048-010</name>
      <address>
        <city>Wrocław</city>
        <zip>51-314</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-003</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-005</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1619</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-001</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-013</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-007</name>
      <address>
        <city>Kuilsrivier</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-004</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-006</name>
      <address>
        <city>Pretoria</city>
        <zip>184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 11027-011</name>
      <address>
        <city>Welkom</city>
        <zip>9459</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-005</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-008</name>
      <address>
        <city>Kharkiv</city>
        <zip>61444</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-004</name>
      <address>
        <city>Kiev</city>
        <zip>3115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-009</name>
      <address>
        <city>Kiev</city>
        <zip>3115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-001</name>
      <address>
        <city>Kyiv</city>
        <zip>2002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-002</name>
      <address>
        <city>Kyiv</city>
        <zip>3037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-003</name>
      <address>
        <city>Kyiv</city>
        <zip>3049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-007</name>
      <address>
        <city>Lviv</city>
        <zip>79060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11380-006</name>
      <address>
        <city>Uzhhorod</city>
        <zip>8800</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-006</name>
      <address>
        <city>Edgbaston</city>
        <state>Birmingham</state>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-022</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 2RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-023</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 4BR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-021</name>
      <address>
        <city>Timperley</city>
        <state>Cheshire</state>
        <zip>WA14 5PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-012</name>
      <address>
        <city>Liskeard</city>
        <state>Cornwall</state>
        <zip>PL14 3XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-009</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-019</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL5 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-014</name>
      <address>
        <city>Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-004</name>
      <address>
        <city>Waterloo</city>
        <state>Liverpool</state>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-027</name>
      <address>
        <city>Davyhulme</city>
        <state>Manchester</state>
        <zip>M41 7WJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-028</name>
      <address>
        <city>Bollington</city>
        <zip>SK10 5JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-026</name>
      <address>
        <city>Bury</city>
        <zip>BL9 ONJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-007</name>
      <address>
        <city>Cardiff</city>
        <zip>CF15 9SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-024</name>
      <address>
        <city>Cheadle Hulme</city>
        <zip>SK8 5LL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-010</name>
      <address>
        <city>Derby</city>
        <zip>S40 4AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-001</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-008</name>
      <address>
        <city>Hexham</city>
        <zip>NE46 1QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-020</name>
      <address>
        <city>Macclesfield</city>
        <zip>SK11 6JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-025</name>
      <address>
        <city>Manchester</city>
        <zip>M14 6WP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-005</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-029</name>
      <address>
        <city>Manchester</city>
        <zip>M20 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-003</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site - 11044-002</name>
      <address>
        <city>Stockton</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <results_first_submitted>June 30, 2020</results_first_submitted>
  <results_first_submitted_qc>August 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2020</results_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inclisiran sodium</keyword>
  <keyword>ASCVD</keyword>
  <keyword>LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03400800/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03400800/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inclisiran</title>
          <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months&#xD;
Inclisiran Sodium: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months&#xD;
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="810"/>
                <participants group_id="P2" count="807"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="772"/>
                <participants group_id="P2" count="770"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inclisiran</title>
          <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months&#xD;
Inclisiran Sodium: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months&#xD;
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="810"/>
            <count group_id="B2" value="807"/>
            <count group_id="B3" value="1617"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="366"/>
                    <measurement group_id="B3" value="733"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="443"/>
                    <measurement group_id="B2" value="441"/>
                    <measurement group_id="B3" value="884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="8.29"/>
                    <measurement group_id="B2" value="64.8" spread="8.68"/>
                    <measurement group_id="B3" value="64.8" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="457"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="579"/>
                    <measurement group_id="B2" value="581"/>
                    <measurement group_id="B3" value="1160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="791"/>
                    <measurement group_id="B2" value="796"/>
                    <measurement group_id="B3" value="1587"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                    <measurement group_id="B2" value="357"/>
                    <measurement group_id="B3" value="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="231"/>
                    <measurement group_id="B3" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in LDL-C From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 millilitres (mL) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1.5 mL) administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in LDL-C From Baseline to Day 510</title>
          <population>ITT population</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.3" lower_limit="-51.22" upper_limit="-47.48"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.62" upper_limit="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-53.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.66</ci_lower_limit>
            <ci_upper_limit>-50.35</ci_upper_limit>
            <estimate_desc>Represents the least squares means difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540</title>
        <time_frame>Baseline, Day 90 to Day 540</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 millilitres (mL) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1.5 mL) administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540</title>
          <population>ITT population</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.82" lower_limit="-47.52" upper_limit="-44.13"/>
                    <measurement group_id="O2" value="3.35" lower_limit="1.65" upper_limit="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-49.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.57</ci_lower_limit>
            <ci_upper_limit>-46.77</ci_upper_limit>
            <estimate_desc>Represents the least squares means difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change In LDL-C From Baseline To Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 millilitres (mL) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1.5 mL) administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change In LDL-C From Baseline To Day 510</title>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.91" lower_limit="-53.14" upper_limit="-48.67"/>
                    <measurement group_id="O2" value="0.96" lower_limit="-1.26" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-51.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.01</ci_lower_limit>
            <ci_upper_limit>-48.72</ci_upper_limit>
            <estimate_desc>Represents the least squares means difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540</title>
        <time_frame>Baseline, Day 90 to Day 540</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 millilitres (mL) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1.5 mL) administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540</title>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.63" lower_limit="-50.37" upper_limit="-46.89"/>
                    <measurement group_id="O2" value="0.31" lower_limit="-1.42" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-48.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.39</ci_lower_limit>
            <ci_upper_limit>-46.48</ci_upper_limit>
            <estimate_desc>Represents the least squares means difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 millilitres (mL) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1.5 mL) administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510</title>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.64" lower_limit="-65.55" upper_limit="-61.74"/>
                    <measurement group_id="O2" value="15.62" lower_limit="13.72" upper_limit="17.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-79.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-81.97</ci_lower_limit>
            <ci_upper_limit>-76.57</ci_upper_limit>
            <estimate_desc>Represents the least squares means difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Total Cholesterol From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 millilitres (mL) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1.5 mL) administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Cholesterol From Baseline to Day 510</title>
          <population>ITT Population</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.00" lower_limit="-29.40" upper_limit="-26.60"/>
                    <measurement group_id="O2" value="1.79" lower_limit="0.38" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-29.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.78</ci_lower_limit>
            <ci_upper_limit>-27.81</ci_upper_limit>
            <estimate_desc>Represents the least squares means difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 millilitres (mL) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1.5 mL) administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510</title>
          <population>ITT Population</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.15" lower_limit="-39.76" upper_limit="-36.54"/>
                    <measurement group_id="O2" value="0.79" lower_limit="-0.82" upper_limit="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-38.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.21</ci_lower_limit>
            <ci_upper_limit>-36.67</ci_upper_limit>
            <estimate_desc>Represents the least squares means difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Non-HDL-C From Baseline to Day 510</title>
        <time_frame>Baseline, Day 510</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Inclisiran</title>
            <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 millilitres (mL) administered as a subcutaneous injection on Day 1, Day 90, and then every 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (1.5 mL) administered as a subcutaneous injection of sterile saline solution (0.9% sodium chloride in water for injection) on Day 1, Day 90, and then every 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Non-HDL-C From Baseline to Day 510</title>
          <population>ITT Population</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="810"/>
                <count group_id="O2" value="807"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.16" lower_limit="-43.09" upper_limit="-39.24"/>
                    <measurement group_id="O2" value="2.15" lower_limit="0.22" upper_limit="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The a priori threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-43.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.04</ci_lower_limit>
            <ci_upper_limit>-40.60</ci_upper_limit>
            <estimate_desc>Represents the least squares means difference from Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>17 months</time_frame>
      <desc>The Efficacy population was comprised of 807 (Placebo) and 810 (Inclisiran) for a toal of 1617 subjects. The Safety population consisted of 804 (Placebo) and 811 (Inclisiran). The reason for this discrepancy is because two randomized subjects (Placebo) were not dosed, so were randomized in error. In addition, a placebo subject received inclisiran at Day 450 so was reallocated into the inclisiran group for safety as per the definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>Inclisiran</title>
          <description>Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months&#xD;
Inclisiran Sodium: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months&#xD;
Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Paroxysmal arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Chest wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Neuroborreliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pathogen resistance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Arterial bypass occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Coronary vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peripheral arterial reocclusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Periprocedural myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Inclusion body myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Intervertebral disc space narrowing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Soft tissue necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Undifferentiated connective tissue disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the stomach</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Linitis plastica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Oral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peripheral nerve sheath tumour malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Tracheal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis membranous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Granulomatosis with polyangiitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Iliac artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Thromboangiitis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="331" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="319" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="804"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="811"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="804"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice-President, Regulatory Operations</name_or_title>
      <organization>Novartis</organization>
      <phone>973-985-0597</phone>
      <email>frank.bosley@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

